Pharmaceutical and healthcare online databases.
Over 200,000 approved drugs and health products.


Trade name of the product:
Pharmaceutical active ingredients:
  • Chlorpheniramine Maleate
  • Dextromethorphan Hydrobromide
  • Noscapine
  • Available forms, composition and doses of Tilomix:
  • Caplets; Oral; Chlorpheniramine Maleate 1 mg; Dextromethorphan Hydrobromide 10 mg; Noscapine 10 mg
  • Suspension; Oral; Chlorpheniramine Maleate 10 mg; Dextromethorphan Hydrobromide 10 mg; Noscapine 10 mg / 5 ml
  • Medical categories:
  • Human:
  • Cough and cold preparations
  • Indications and usages, anatomical therapeutic chemical and diseases classification codes:
  • R05CA10 - Expectorants, combinations
  • Pharmaceutical companies: manufacturers, researchers, developers, local distributors and suppliers:
  • Nufarindo Pharmaceutical Laboratories
  • Find online pharmacy, drugstore, pharma or beauty shop where to order or buy Tilomix brand or generic online:

  • Buy Tilomix online

  • Comments

    11 Apr 2014, 00:08
    that arterolane mtelaae is not a NCE. I've only said that Synriam is not a NCE and Ranbaxy's press release seems to be quite clear that Synriam is a FDC and the impression given by the press release is that the invention lies in creation of the FDC. No where does Ranbaxy claim that their invention lies in the development of a NCE, although I'm not denying that this could be the case. Also, I never 'cast aside' or belittled Ranbaxy's achievement. In fact I used the word 'commendable' - I was only critical of some of the media reports which seem to indicate that this was the first time that an Indian company invented a FDC. As for the rhetoric over it being an Indian drug, I think we need to collect more information before jumping to any conclusions. From the information that I have been able to gather, Ranbaxy is pretty much a Japanese company, the drug in question is reportedly being manufactured by Ranbaxy in its Chinese plants and the drug itself was discovered initially by a Swiss non-profit - MMV, with a team consisting largely of foreign scientists. If I have tracked the right patent for the drug in question then in that case it is quite clear that only 2 of the 9 inventors of this drug are Indians, while one is of Indian origin. I could be wrong on this patent and I'm waiting for confirmation on the patent covering the drug. From what I gather Ranbaxy took over only at the stage of clinical trials. And yes, they deserve credit for taking the risk of investing and conducting large scale clinical trials but even for the clinical trials they received funding from the govt. So there really wasn't much risk. Which ever way you look at it Ranbaxy does deserve credit for cracking this new public private mode of development. Regards,Prashant
    Notify me about new comments on this page
    Hide my email

    Pharmaceutical Drugs | Health Products | Sitemap | About

    Copyright © 2005-2013 Drugs-about.com. All rights reserved.